Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist

Translational Oncology

Volumn 5, Issue 1, 2012, Pages 39-47

  Kim, Sun Jin ^a   Kim, Jang Seong ^a   Kim, Seung Wook ^a   Yun, Seok Joong ^a   He, Junqin ^a   Brantley, Emily ^a   Fan, Dominic ^a   Strickner, Panja ^b   Lehembre, François ^b   Regenass, Urs ^b   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ENDOTHELIN RECEPTOR; MACITENTAN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE B; SODIUM CHLORIDE; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER INCIDENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG SENSITIZATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CARCINOMA; PERITONEAL CAVITY; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84862961320     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11286     Document Type: Article

References (41)

1. Jemal A, Siegal R, Ward E, Hao Y, Xu J, and Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
2. Cannistra SA (1993). Cancer of the ovary. N Engl J Med 329, 1550-1559.
3. Gore ME (2001). Treatment of relapsed epithelial ovarian cancer. In American Society of Clinical Oncology 2001 Education Book. American Society of Clinical Oncology, Alexandria, VA. pp. 468-476.
4. Talmadge JE and Fidler IJ (2010). AACR Centennial Series: the biology of cancer metastasis: historical perspective. Cancer Res 70, 5649-5669.
5. Gottesman MM and Pastan I (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62, 385-427.
6. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis CJ, Mathew P, Wang X, et al. (2006). Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98, 783-793.
7. Kim SJ, Kim JS, Kim SW, Brantley E, Yun SJ, He J, Maya M, Zhang F, Wu Q, Lehembre F, et al. (2011). Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia 13, 167-179.
8. Levin ER (1995). Endothelins. N Engl J Med 333, 356-363.
9. Bloch KD, Friedrich SP, Lee ME, Eddy RL, Shows TB, and Quertermous T (1989). Structural organization and chromosomal assignment of the gene encoding endothelin. J Biol Chem 264, 10851-10857.
10. Goldie RG (1999). Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol 26, 145-148.
11. Opgenorth TJ (1995). Endothelin receptor antagonism. Adv Pharmacol 33, 1-65.
12. Clozel M (2000). Endothelin receptor antagonists: current status and perspectives. J Cardiovasc Pharmacol 35, S65-S68.
13. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, duBois RM, Black CM, et al. (2004). Endothelin-1 promotes myofibroblasts induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibro tic fibroblasts. Mol Biol Cell 15, 2707-2719.
14. Yang Z, Krasnici N, and Lüscher TF (1999). Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 100, 5-8.
15. Hocher B, Schwarz A, Fagan KA, Thöne-Reineke C, El-Hag K, Kusserow H, Elitok S, Bauer C, Neumayer HH, Rodman DM, et al. (2000). Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 23, 19-26.
16. Nelson J, Bagnato A, Battistini B, and Nisen P (2003). The endothelin axis: emerging role in cancer. Nat Rev Cancer 3, 110-116.
17. Spinella F, Garrafa E, Di Castro V, Rosano L, Nicotra MR, Caruso A, Natali PG, and Bagnato A (2009). Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res 69, 2669-2676.
18. Sonveaux P, Dessy C, Martinive P, Havaux X, Jordan BF, Gallez B, Grégoire V, Balligand JL, and Feron O (2004). Endothelin-1 is a critical mediator of mitogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res 64, 3209-3214.
19. Rosanò L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, Natali PG, and Bagnato A (2005). Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 65, 11649-11657.
20. Pristivishalil G and Nelson JB (2000). Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 44, 44-77.
21. Ahmed SI, Thompson J, Coulson JM, and Woll PJ (2000). Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 22, 422-431.
22. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, Burnstock G, and Taylor I (2001). Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer 85, 1759-1763.
23. Pflug BR, Zheng H, Udan MS, D'Antonio JM, Marshall FF, Brooks JD, and Nelson JB (2007). Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett 246, 139-148.
24. Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra MR, Natali PG, and Venuti A (2002). Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 62, 6381-6384.
25. Egidy G, Eberl LP, Valdenaire OV, Irmler M, Majdi R, Diserens A-C, Fontana A, Janzer R-C, Pinet F, and Juillerat-Jeanneret L (2000). The endothelin system in human glioblastoma. Lab Invest 80, 1681-1689.
26. Rosanò L, Di Castro V, Spinella F, Nicotra MR, Natali PG, and Bagnato A (2007). ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 6, 2003-2011.
27. Rayhman O, Klipper E, Muller L, Davidson B, Reich R, and Meidan R (2008). Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res 68, 9265-9273.
28. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, and Bagnato A (2009). β-Arrestin links endothelin A receptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106, 2806-2811.
29. Bagnato A, Loizidou M, Pflug BR, Curwen J, and Growcott J (2011). Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 163, 220-233.
30. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, et al. (2008). Pharmacology of macitentan, an orally active tissue targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327, 736-745.
31. Fidler IJ (2003). The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited (Timeline). Nat Rev Cancer 3, 453-458.
32. Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Sood AK, and Fidler IJ (2005). Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 11, 4923-4933.
33. Zahedi P, De Souza R, Huynk L, Piquette-Miller M, and Allen C (2011). Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer. Mol Pharm 8, 260-269.
34. Agarwal R and Kaye SB (2003). Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3, 502-516.
35. Stewart DJ (2007). Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63, 12-31.
36. Hooks SB, Callihan P, Altman MK, Hurst JH, Ali MW, and Murph MM (2010). Regulators of G-protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol Cancer 9, 289-304.
37. Kulasekaran P, Scavone CA, Rogers DS, Arenburg DA, Thannickal VJ, and Jorowitz JC (2009). Endothelin-1 and transforming growth factor-β1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir CellMol Biol 41, 484-493.
38. Eberl LP, Egidy G, Pinet F, and Juillerat-Jeanneret L (2000). Endothelin receptor blockade potentiates FasL-induced apoptosis in colon carcinoma cells via the protein kinase C pathway. J Cardiovasc Pharmacol 36, S354-S356.
39. Vacca F, Bagnato A, Catt KJ, and Tecce R (2000). Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 60, 5310-5317.
40. Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor S, Nelson JB, and Pflug B (2006). Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 8, 725-732.
41. Fidler IJ (1995). Modulation of the organ microenvironment for the treatment of cancer metastasis. J Natl Cancer Inst 87, 1588-1592.